CERO Valuation

CERo Therapeutics Holdings Inc

Add to Watchlist

Advanced Chart

7.520

-0.15(-1.956%)1D

Overview
Forecast
Valuation
Earnings

CERO Relative Valuation

CERO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CERO is overvalued; if below, it's undervalued.

Historical Valuation

CERo Therapeutics Holdings Inc (CERO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.03. The fair price of CERo Therapeutics Holdings Inc (CERO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：7.67

Fair

-0.27

Trailing

Forward

0.00

EV/EBITDA

CERo Therapeutics Holdings Inc. (CERO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.66

EV/EBIT

CERo Therapeutics Holdings Inc. (CERO) has a current EV/EBIT of -0.66. The 5-year average EV/EBIT is -0.03. The thresholds are as follows: Strongly Undervalued below -0.21, Undervalued between -0.21 and -0.12, Fairly Valued between 0.06 and -0.12, Overvalued between 0.06 and 0.15, and Strongly Overvalued above 0.15. The current Forward EV/EBIT of -0.66 falls within the Strongly Undervalued range.

0.00

CERo Therapeutics Holdings Inc. (CERO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-0.62

P/OCF

CERo Therapeutics Holdings Inc. (CERO) has a current P/OCF of -0.62. The 5-year average P/OCF is -0.04. The thresholds are as follows: Strongly Undervalued below -0.27, Undervalued between -0.27 and -0.15, Fairly Valued between 0.08 and -0.15, Overvalued between 0.08 and 0.19, and Strongly Overvalued above 0.19. The current Forward P/OCF of -0.62 falls within the Strongly Undervalued range.

-0.45

P/FCF

CERo Therapeutics Holdings Inc. (CERO) has a current P/FCF of -0.45. The 5-year average P/FCF is -0.03. The thresholds are as follows: Strongly Undervalued below -0.20, Undervalued between -0.20 and -0.11, Fairly Valued between 0.06 and -0.11, Overvalued between 0.06 and 0.14, and Strongly Overvalued above 0.14. The current Forward P/FCF of -0.45 falls within the Strongly Undervalued range.

CERo Therapeutics Holdings Inc (CERO) has a current Price-to-Book (P/B) ratio of -0.90. Compared to its 3-year average P/B ratio of -4.92 , the current P/B ratio is approximately -81.75% higher. Relative to its 5-year average P/B ratio of -8.41, the current P/B ratio is about -89.33% higher. CERo Therapeutics Holdings Inc (CERO) has a Forward Free Cash Flow (FCF) yield of approximately -140.37%. Compared to its 3-year average FCF yield of -122.54%, the current FCF yield is approximately 14.56% lower. Relative to its 5-year average FCF yield of -105.53% , the current FCF yield is about 33.02% lower.

-0.90

P/B

Median3y

-4.92

Median5y

-8.41

-140.37

FCF Yield

Median3y

-122.54

Median5y

-105.53

Competitors Valuation Multiple

The average P/S ratio for CERO's competitors is 8.74, providing a benchmark for relative valuation. CERo Therapeutics Holdings Inc Corp (CERO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CERO.O

CERo Therapeutics Holdings Inc

Carisma Therapeutics Inc

Sensei Biotherapeutics Inc

Performance Decomposition

Market capitalization of CERO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CERO in the past 1 year is driven by Unknown.